Core Viewpoint - Merck & Co., Inc. is positioning itself for long-term growth with a projected revenue of $70 billion from emerging businesses by the mid-2030s, despite increasing competition in its cancer therapy Keytruda [2]. Group 1: Revenue Projections - The company expects cardiometabolic and respiratory treatments to generate $20 billion, an increase from a prior forecast of $15 billion [3]. - Infectious disease drugs are projected to reach $15 billion, up from a previous estimate of $5 billion, reflecting accelerated launch plans and an expanding late-stage pipeline [3]. Group 2: Strategic Acquisitions - Merck is pursuing a $28-32 billion acquisition of Revolution Medicines, which could add over $10 billion in risk-adjusted global sales by 2035 [4]. - This acquisition aims to offset patent expirations and strengthen Merck's oncology pipeline [4]. Group 3: Company Overview - Merck & Co., Inc. is a healthcare provider that offers pharmaceuticals, vaccines, biologics, and animal health products, focusing on innovation and pipeline expansion [5].